Filing Details

Accession Number:
0001599901-24-000010
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-23 15:12:39
Reporting Period:
2024-01-20
Accepted Time:
2024-01-23 15:12:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1599901 Avidity Biosciences Inc. RNA Pharmaceutical Preparations (2834) 461336960
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1841990 Michael W. Flanagan C/O Avidity Biosciences, Inc.
10578 Science Center Drive, Suite 125
San Diego CA 92121
Csto No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-01-20 20,000 $0.00 20,290 No 4 A Direct
Common Stock Disposition 2024-01-22 4,129 $10.13 35,871 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2024-01-20 88,000 $0.00 88,000 $10.16
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
88,000 2034-01-19 No 4 A Direct
Footnotes
  1. Represents restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in four equal installments on the first four anniversaries of January 20, 2024, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
  2. Includes 290 shares previously acquired by the Reporting Person under the Avidity Biosciences, Inc. 2020 Employee Stock Purchase Plan.
  3. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs on January 20, 2024. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1.
  4. 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 20, 2024 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date.